Life Biosciences says it just dosed its first patient in an FDA-approved clinical trial to reverse age-related blindness.

The first participant has been treated in a landmark clinical trial of cellular reprogramming, which aims to rejuvenate ageing cells.

Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now being tested in humans.